麩質過敏症:市場焦點

全球麩質過敏症2019年血清陽性的患病人數約1億2,110萬人，以切片檢查證明的麩質過敏症的患病人數估計4,800萬人。

本報告提供麩質過敏症的相關調查，主要開發平台藥物，最近的活動和分析師的見解，臨床試驗，今後的活動，成功性，10年的疾病盛行率預測，授權與競爭情形等資訊。

目錄

內容

概要

要點

病的背景

處理

流行病學

開發平台藥物

最近的事件和分析師的見解

• 麩質過敏症用TAK-101(2019年10月21日)

今後主要的活動

成功的概率

授權及資產取得的交易

• Takeda以最大3億3,000萬美元收購Celiac Venture PvP
• 形成醫療產業的交易(2020年2月)

臨床試驗情勢

• 各狀態的贊助商
• 各階段的贊助商

參考文件

附錄

圖的清單

表格的清單

This Market Spotlight report covers the Celiac Disease market, comprising key pipeline drugs, recent events and analyst opinion, clinical trials, upcoming events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals.

Key Takeaways:

Datamonitor Healthcare estimates that in 2019, there were approximately 121.1 million seropositive prevalent cases of celiac disease and 48.0 million prevalent cases of biopsy-proven celiac disease worldwide.

Pooled seroprevalence is estimated to be 1.4%, and the pooled prevalence of biopsy-proven disease is estimated to be 0.7% worldwide.

Half of the industry-sponsored drugs in active clinical development for celiac disease are in Phase II, with only one drug in Phase III.

Therapies in development for celiac disease focus on targets such as zonulin and zonulin receptor, interleukin-15/interleukin-15 receptor, and gluten. Pipeline drugs for celiac disease are administered via the oral and intravenous routes.

The release of topline Phase III trial results for INN-202 is the only high-impact upcoming event in the celiac disease space. The overall likelihood of approval of a Phase I autoimmune/immunology asset is 12.3%, and the average probability a drug advances from Phase III is 66.9%. Drugs, on average, take 9.2 years from Phase I to approval in the overall autoimmune/immunology space.

All clinical trials for celiac disease have been in either Phase I or Phase II.

The US has the highest number of celiac disease clinical trials globally. Clinical trial activity in the celiac disease space is dominated by completed trials. 9 Meters Biopharma has the highest number of completed clinical trials for celiac disease, with six trials.

9 Meters Biopharma leads industry sponsors with the highest overall number of clinical trials for celiac disease.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

• Subtypes

TREATMENT

EPIDEMIOLOGY

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

• TAK-101 for Celiac Disease (October 21, 2019)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

• Takeda Acquires Celiac Venture PvP For Up To $330m
• Deals Shaping The Medical Industry, February 2020

CLINICAL TRIAL LANDSCAPE

• Sponsors by status
• Sponsors by phase

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

• Figure 1: Overview of pipeline drugs for celiac disease in the US
• Figure 2: Pipeline drugs for celiac disease, by company
• Figure 3: Pipeline drugs for celiac disease, by drug type
• Figure 4: Pipeline drugs for celiac disease, by classification
• Figure 5: TAK-101 for Celiac Disease (October 21, 2019): Phase IIa - Safety & Efficacy
• Figure 6: Key upcoming events in celiac disease
• Figure 7: Probability of success in the autoimmune/immunology pipeline
• Figure 8: Clinical trials in celiac disease
• Figure 9: Top 10 drugs for clinical trials in celiac disease
• Figure 10: Top 10 companies for clinical trials in celiac disease
• Figure 11: Trial locations in celiac disease
• Figure 12: Celiac disease trials status
• Figure 13: Celiac disease trials sponsors, by phase

LIST OF TABLES

• Table 1: Prevalent cases of celiac disease, by definition, 2019
• Table 2: Prevalence of celiac disease, by definition
• Table 3: Pipeline drugs for celiac disease in the US
• Table 4: TAK-101 for Celiac Disease (October 21, 2019)